Morgan Stanley Minerva Neurosciences, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Minerva Neurosciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 11,004 shares of NERV stock, worth $15,515. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,004

Previous 16,104 31.67%

Holding current value

$15,515

Previous $35,000 48.57%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.53 - $2.68 $7,803 - $13,668	-5,100 Reduced 31.67%	11,004 $18,000
Q4 2024 Feb 14, 2025	BUY	$2.1 - $2.7 $11,249 - $14,463	5,357 Added 49.85%	16,104 $35,000
Q2 2024 May 14, 2025	SELL	$2.33 - $3.65 $12,481 - $19,553	-5,357 Reduced 33.27%	10,747 $34,000
Q1 2024 Aug 16, 2024	BUY	$2.5 - $12.47 $11,152 - $55,628	4,461 Added 70.97%	10,747 $27,000
Q1 2024 May 15, 2024	BUY	$2.5 - $12.47 $11,152 - $55,628	4,461 Added 70.97%	10,747 $27,000
Q4 2023 Aug 16, 2024	SELL	$3.96 - $7.85 $17,665 - $35,018	-4,461 Reduced 41.51%	6,286 $38,000
Q4 2023 Feb 13, 2024	SELL	$3.96 - $7.85 $28,983 - $57,454	-7,319 Reduced 53.8%	6,286 $38,000
Q3 2023 Nov 15, 2023	BUY	$6.9 - $13.05 $31,809 - $60,160	4,610 Added 51.25%	13,605 $93,000
Q2 2023 Aug 14, 2023	BUY	$1.62 - $10.19 $680 - $4,279	420 Added 4.9%	8,995 $82,000
Q1 2023 May 15, 2023	SELL	$1.51 - $3.09 $151 - $309	-100 Reduced 1.15%	8,575 $13,000
Q4 2022 Feb 14, 2023	SELL	$1.43 - $13.43 $7,069 - $66,397	-4,944 Reduced 36.3%	8,675 $13,000
Q3 2022 Nov 14, 2022	BUY	$2.53 - $13.17 $16,766 - $87,277	6,627 Added 94.78%	13,619 $126,000
Q2 2022 Aug 15, 2022	BUY	$2.7 - $7.68 $18,878 - $53,698	6,992 New	6,992 $23,000

Others Institutions Holding NERV

# of Institutions

Shares Held

1.95M

Call Options Held

Put Options Held

View Full List

About Minerva Neurosciences, Inc.

Ticker NERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,340,190
Market Cap $7.53M
Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein ...

More about NERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account